Understanding how cells maintain protein balance is essential to addressing diseases caused by protein accumulation such as cancer or neurodegenerative disorders. We’re advancing the science behind targeted protein degradation to develop therapies with the potential to transform patient outcomes. Discover how this insight is fueling potential breakthroughs that may improve the future of treatment: https://bit.ly/3L0qUrO #OneBMS
Bristol Myers Squibb
Pharmaceutical Manufacturing
Lawrence Township, NJ 1,738,690 followers
About us
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
- Website
-
http://www.bms.com
External link for Bristol Myers Squibb
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Lawrence Township, NJ
- Type
- Public Company
- Specialties
- biotechnology, innovation, great place to work, pharmaceuticals, research and development, and healthcare
Locations
Employees at Bristol Myers Squibb
Updates
-
#InspireForCancer : un nouveau regard sur l'espoir Une exposition inédite imaginée par #BMSFrance ,où l’art et la science s’unissent autour du souffle, expression de vie, de force et d’espoir. À travers une expérience immersive mêlant créations artistiques, témoignages et innovations scientifiques, #InspireForCancer propose un regard sensible et engagé dans la lutte contre le cancer du poumon. Une invitation à voir, à ressentir, à inspirer. Avec Patients en Réseau et pour soutenir un projet de recherche de l’ Institut Paoli-Calmettes avec l’APHM (Assistance Publique - Hopitaux de Marseille). 📍Rendez-vous du 17 au 22 novembre : A la Galerie Jouenne, de Marseille – 41 rue Montgrand – entrée gratuite. - Sur nos réseaux sociaux pour découvrir cette opération et le travail des artistes !
-
At #ACR25, we’re looking forward to sharing how we’re advancing science in rheumatology. From understanding immune pathways to personalizing care, our goals remain the same: tailor therapies to individual needs, improve outcomes and expand treatment options. For more than two decades, we’ve been at the forefront of immunology research, beginning with rheumatoid arthritis and expanding into a variety of disease states. Explore how we’re shaping the future of rheumatic disease research: https://bit.ly/3L6iizM #OneBMS
-
-
At the 2025 Fall Clinical Dermatology Conference, we’ll share real-world data on our approved, once-daily oral treatment for moderate-to-severe plaque psoriasis—a condition that can impact health, quality of life and work productivity. We’re committed to advancing care for the psoriasis community, with the goal of bringing symptom relief to those affected. Learn more about the global burden of psoriasis: https://bit.ly/43cRy6W #FC25 #OneBMS
-
-
“Making sure that we all can show up with our best selves, whatever that looks like that day, and making it a team sport. That's, I think, what's most important.” In the latest episode of our Trials to Transformation series, our CEO Chris Boerner shares his perspective on the daily scrum we all find ourselves in. #TrialstoTransformation #OneBMS
-
Through our diversified portfolio and breadth of novel modalities, we are working to deliver new hope to patients living with cancer. Thank you to the patients, doctors, investigators and researchers that make this progress possible. #ESMO25
-
-
Targeted protein degradation (TPD) is reshaping the boundaries of drug discovery. In his recent article, Robert Plenge shares his perspective on the latest innovation in the field and how our teams are poised to turn bold science into firsts for patients. #OneBMS
Early in my career as a physician-scientist, I learned a humbling lesson: just because we have a strong biological understanding of a disease, doesn’t always mean there’s a clear path to treatment. But, in the years since, advancements like targeted protein degradation (TPD) have offered us a new way forward – and now, we continue to redraw the boundaries of what’s possible. Today, the latest innovations in TPD – from small-molecule degraders such as CELMoD agents to next-generation approaches like degrader-antibody conjugates (DACs) – represent a fundamental shift in how we approach disease. As pioneers in this space, Bristol Myers Squibb is leading the way. In my latest article, I reflect on how transformative science, decades of expertise and new technologies are converging to push the boundaries of what’s possible in drug discovery. #BMS_Employee
-
💡Fast Fact: Colorectal cancer (CRC) is the third most common cancer worldwide, and its incidence rate has nearly doubled among younger adults in the U.S. since the early 1990s. Yet, it is also one of the most preventable cancers and highly treatable when caught early. On the latest episode of DoctoRx Unscripted, Tania Small, MD, SVP and head of Global Medical Affairs, sits down with Dr. Heinz-Josef Lenz, one of the world’s greatest minds in gastrointestinal medical research, to discuss the future of CRC care. Together, they unpack the root causes behind the rising incidence rates of early-onset CRC and explore the cutting-edge innovations that are reshaping detection and treatment of the disease. They also examine how lifestyle choices, disparities in access and patient-driven data are impacting survival. If you're driving change in oncology, this is your must-listen: https://bit.ly/3Ja1xDm #OneBMS #DoctoRxUnscripted
-
As we reflect on this year’s #ESMO25, we are inspired by the continued dedication of the scientific community. Through our oncology portfolio, potential of our research pipeline and our novel mechanisms and unique modalities, we are hopeful we can bring renewed hope to difficult-to-treat patient populations.
-
We are committed to elevating our understanding of lupus and improving clinical trial designs to better address the variability of the disease from patient to patient. As a complex condition that manifests in a variety of organ systems, new, innovative approaches to treatment are needed. Our goal is to go beyond small improvements to bring potentially life-changing therapies to patients living with immune-mediated diseases. Read more from Liz Colston, MD, PhD about how we’re advancing pathbreaking science to push the boundaries of what’s possible in lupus research. #OneBMS